RecruitingNot ApplicableNCT06630845
Comparison of Whole Body DWI to FDG PET
Comparison of Whole Body DWI to FDG PET Using PET/MRI
Sponsor
University of California, San Francisco
Enrollment
30 participants
Start Date
Feb 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years.
- Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI.
- Ability to understand a written informed consent document, and the willingness to sign it.
- Diagnosis of metastatic cancer.
Exclusion Criteria2
- Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
- Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGFluorodeoxyglucose F18
Given IV as part of routine imaging
PROCEDUREPositron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
Imaging procedure
PROCEDUREWhole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
Imaging procedure done concurrently with PET/MRI
DEVICEGeneral Electric (GE) SIGNA PET/MR
Imaging device
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06630845
Related Trials
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT0526762618 locations
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT071440851 location
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT0573508018 locations
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT063461974 locations
Optimizing Y90 Therapy for Radiation Lobectomy
NCT043907242 locations